There now do seem to be sufficient supplies of Rybelsus (oral semaglutide) to permit switching of patients on injectable agents, who have not been able to source an injection for more than 2 weeks.
Please remember that there is a relative contraindication with Rybelsus for patients with diabetic retinopathy, although clearly for those with mild (background) retinopathy the risk of progression is very low and the risk benefit would almost certainly be in favour of a switch. Please also remember that Rybelsus must be taken on an empty stomach with no medication or fluids for at least 30 minutes afterwards.
For further information please find below the latest MSAN on availability of GLP-1 agonists.
